增长差异化因子-15与心力衰竭患者的不良结果之间的关联:系统性文献综述
Ali Javaheri1,2, Mualla Ozcan1, Lauren Moubarak3
1Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Heliyon
|September 4, 2024
概括
增长差异化因子15 (GDF-15) 预测心力衰竭 (HF) 患者的不良结果. 高GDF-15水平与增加的死亡率,住院和较差的功能有关,有助于风险预测.
科学领域:
- 心血管疾病中的生物标志物
- 心力衰竭的预后指标
- 在GDF-15中进行翻译研究.
背景情况:
- 增长差异化因子15 (GDF-15) 被认为是各种临床条件中的潜在生物标志物.
- 它在心力衰竭 (HF) 和相关不良结果中的作用需要全面评估.
研究的目的:
- 系统地审查有关GDF-15度与心力衰竭 (HF) 患者不良结果之间的相关性文献.
- 评估GDF-15作为HF死亡率和其他不良事件的独立预测因子.
主要方法:
- 按照PRISMA的指导方针进行了一次系统文献审查 (SLR).
- 在Embase和Medline数据库中对2014年1月至2022年8月的出版物进行搜索.
- 包括63篇出版物 (55篇手稿,8篇摘要),包括观察性研究和随机对照试验 (RCT) 的后期分析.
主要成果:
- 在纵向研究中,更高的基线GDF-15度与所有原因死亡率 (92%),心血管死亡率 (80%) 和复合结果 (68%) 的风险增加显著相关.
- 截面分析显示,较差的功能 (100%) 和运动能力 (75%) 与较高的GDF-15.5%相关.
- 经常报告的结果包括死亡率,复合结果,住院/再住院和功能.
结论:
- GDF-15是心力衰竭患者死亡率和其他不良,非致命结果的独立预测因素.
- 了解GDF-15的预后价值可以提高HF的临床风险预测模型.
- 这种生物标志物可以帮助优化心力衰竭患者的治疗策略.
更多相关视频
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:28Role of Hematopoietic Growth Factors
1.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.3K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545